OM:CRAD B

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

C-Rad AB (publ), together with its subsidiaries, develops, manufactures, and sells systems with applications in radiation therapy for the treatment of cancer worldwide. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has C-Rad's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CRAD B has not had significant price volatility in the past 3 months.


Market Performance


7 Day Return

-4.7%

CRAD B

-7.1%

SE Medical Equipment

-4.2%

SE Market


1 Year Return

16.3%

CRAD B

11.7%

SE Medical Equipment

9.5%

SE Market

Return vs Industry: CRAD B matched the Swedish Medical Equipment industry which returned 15.7% over the past year.

Return vs Market: CRAD B exceeded the Swedish Market which returned 13.4% over the past year.


Shareholder returns

CRAD BIndustryMarket
7 Day-4.7%-7.1%-4.2%
30 Day2.8%-4.7%-0.8%
90 Day14.3%-0.3%3.6%
1 Year16.3%16.3%13.3%11.7%11.5%9.5%
3 Year1.4%1.4%59.0%40.7%27.5%13.8%
5 Year108.8%106.2%62.3%34.5%54.0%24.2%

Price Volatility Vs. Market

How volatile is C-Rad's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is C-Rad undervalued compared to its fair value and its price relative to the market?

6.49x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: CRAD B (SEK36.7) is trading above our estimate of fair value (SEK12.94)

Significantly Below Fair Value: CRAD B is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: CRAD B is unprofitable, so we can't compare its PE Ratio to the SE Medical Equipment industry average.

PE vs Market: CRAD B is unprofitable, so we can't compare its PE Ratio to the Swedish market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CRAD B's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CRAD B is overvalued based on its PB Ratio (6.5x) compared to the SE Medical Equipment industry average (4.5x).


Next Steps

Future Growth

How is C-Rad forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

22.0%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as C-Rad has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has C-Rad performed over the past 5 years?

36.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CRAD B is currently unprofitable.

Growing Profit Margin: CRAD B is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CRAD B is unprofitable, but has reduced losses over the past 5 years at a rate of 36.6% per year.

Accelerating Growth: Unable to compare CRAD B's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CRAD B is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (18.4%).


Return on Equity

High ROE: CRAD B has a negative Return on Equity (-5.57%), as it is currently unprofitable.


Next Steps

Financial Health

How is C-Rad's financial position?


Financial Position Analysis

Short Term Liabilities: CRAD B's short term assets (SEK201.8M) exceed its short term liabilities (SEK55.3M).

Long Term Liabilities: CRAD B's short term assets (SEK201.8M) exceed its long term liabilities (SEK7.3M).


Debt to Equity History and Analysis

Debt Level: CRAD B is debt free.

Reducing Debt: CRAD B has no debt compared to 5 years ago when its debt to equity ratio was 28.5%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable CRAD B has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: CRAD B is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 24.5% per year.


Next Steps

Dividend

What is C-Rad current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CRAD B's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CRAD B's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CRAD B's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CRAD B's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CRAD B's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.2yrs

Average management tenure


CEO

Tim Thurn (39 yo)

7.25yrs

Tenure

kr2,117,000

Compensation

Mr. Tim Thurn has been the Chief Executive Officer and President of C-Rad AB since July 1, 2013. Mr. Thurn has been the Chief Executive Officer of C-Rad Imaging AB since 2014. He served as the President at ...


CEO Compensation Analysis

Compensation vs Market: Tim's total compensation ($USD242.26K) is about average for companies of similar size in the Swedish market ($USD231.20K).

Compensation vs Earnings: Tim's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Tim Thurn
CEO & President7.25yrskr2.12m0.84%
SEK 10.4m
Henrik Bergentoft
Chief Financial Officer0.58yrno datano data
Håkan Axelsson
Chief Operating Officer1.17yrsno datano data
Xiaodong Wang
President of China2.75yrsno data0.059%
SEK 734.0k
Dirk Freynhagen
President of EIMEA1.17yrsno data0.0059%
SEK 73.4k

1.2yrs

Average Tenure

46yo

Average Age

Experienced Management: CRAD B's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Per-Arne Blomquist Curt
Independent Director1.75yrsno data0.86%
SEK 10.6m
Lars Nyberg
Independent Chairman of the Board4.25yrskr400.00k7.47%
SEK 92.2m
Asa Hedin
Independent Director3.75yrskr200.00kno data
Kicki Wallje-Lund
Independent Director5.75yrskr200.00k0.018%
SEK 220.3k
Peter Hamberg
Independent Director7.42yrskr200.00k2.11%
SEK 26.1m
David Sjöström
Independent Director3.42yrskr200.00kno data

4.0yrs

Average Tenure

58yo

Average Age

Experienced Board: CRAD B's board of directors are considered experienced (4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CRAD B insiders have sold more shares than they have bought in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 8.5%.


Top Shareholders

Company Information

C-Rad AB (publ)'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: C-Rad AB (publ)
  • Ticker: CRAD B
  • Exchange: OM
  • Founded: 2004
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: kr1.235b
  • Shares outstanding: 33.66m
  • Website: https://www.c-rad.se

Number of Employees


Location

  • C-Rad AB (publ)
  • BredgrAend 18
  • Uppsala
  • Uppsala County
  • 753 20
  • Sweden

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CRAD BOM (OMX Nordic Exchange Stockholm)YesClass B SharesSESEKJul 2007
0R44LSE (London Stock Exchange)YesClass B SharesGBSEKJul 2007
CRADBSBATS-CHIXE (BATS 'Chi-X Europe')YesClass B SharesGBSEKJul 2007

Biography

C-Rad AB (publ), together with its subsidiaries, develops, manufactures, and sells systems with applications in radiation therapy for the treatment of cancer worldwide. The company operates through two seg ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/26 22:20
End of Day Share Price2020/10/26 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.